Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Info
    • Snapshot
    • Quote (Nasdaq)
    • Charts (Nasdaq)
    • Historical Data (Nasdaq)
    • Quote (TSX)
    • Charts (TSX)
    • Historical Data (TSX)
    • Analyst Coverage
  • Filings & Financials
    • Reports
    • SEC Filings
    • SEDAR Filings
    • Tax Information (PFIC)
  • Corporate Governance
  • FAQs
  • Email Alerts
  • IR Contacts
Dec 8, 2022

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Dec 1, 2022

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Nov 21, 2022

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

Nov 10, 2022

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Nov 7, 2022

Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

Nov 7, 2022

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Oct 27, 2022

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oct 5, 2022

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Sep 7, 2022

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

Aug 11, 2022

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...59
© 2023 Oncolytics Biotech, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap